Perspective
Our work in Perspective
-
Responding to Some ‘Inconvenient’ Truths About PBMs
The lack of transparency and inability of plan sponsors to assess how much pharmacy benefit managers generate in savings and how much they retain for themselves is the root issue.
Categorized in -
Comments to Representatives DeGette and Bucshon on Building on the Successes of 21st Century Cures
Schaeffer Center experts provided comments to lawmakers on additional measures for enhancing or improving the effectiveness of the 21st Century Cures Act.
Categorized in -
State Mandates to Cap Out-of-Pocket Insulin Costs Are No Longer Necessary
State laws capping patients’ out-of-pocket insulin costs, though well-intentioned, have had limited impact.
Categorized in -
A Patient-Focused, Evidence-Driven Approach to PBM Reform
As policymakers consider reforms to the prescription drug supply chain, they should keep five principles in mind to ensure better outcomes for patients.
Categorized in -
Comments to CMS on Transcatheter Tricuspid Valve Replacement (TTVR) and Broader CED Policy Considerations
Schaeffer Center experts provided comments to CMS on issues with how Coverage with Evidence Determination policy is applied.
Categorized in -
Estimating Overpayments to MA Plans: MedPAC Critics Get It Wrong
Why many of the key assertions in a recent Forefront article challenging the MedPAC’s estimate that favorable selection and upcoding increase payments to Medicare Advantage (MA) plans in 2024 by $83 billion are wrong.
Categorized in -
Access to New Alzheimer’s Treatments Bogged Down by Medicare Policy
There are now two Alzheimer’s treatments with significant clinical benefit. It’s not clear how quickly patients will be able to benefit.
Categorized in -
How To Advance The Debate Over QALYs: A Response To Kaplan et al.
Jason Doctor and Darius Lakdawalla respond to a recent Health Affairs Forefront article by Robert Kaplan and colleagues and call for an alternative to QALYs, given issues with the underlying assumptions.
Categorized in -
Improving Access to Medigap When Beneficiaries Leave Medicare Advantage
For beneficiaries switching from Medicare Advantage, state regulations generally permit Medigap plans to deny coverage, impose waiting periods, or charge higher premiums.
Categorized in -
Let the Market Determine Drug Prices – Not 19th Century Economics
In health care, the term “value” gets lobbed about quite loosely. It is easy to forget that centuries of economic thought have gone into rigorously examining how worth is determined in a marketplace.
Categorized in